Drug
Capmatinib
Capmatinib: highest development phase Phase 2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| capmatinib NCT04926831 | Phase 2 | Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Capmatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.